Vitiligo (Investigational)
Highly investigational adjunct for limited stable vitiligo; case reports only; topical calcineurin inhibitors, narrow-band UVB, and ruxolitinib cream remain primary.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for vitiligo. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for vitiligo is highly investigational.
- What evidence exists?
- Tier C (highly investigational). Only two single-patient case reports were identified (one periocular vitiligo, one in a child who also received other Ayurvedic treatment); no controlled study was found. Evidence-based options per AAD 2023 guideline include topical calcineurin inhibitors (tacrolimus 0.1 percent), topical ruxolitinib cream (FDA-approved 2022 for nonsegmental vitiligo), topical corticosteroids, narrow-band UVB phototherapy (the most effective non-surgical option), excimer laser, and surgical melanocyte transplantation for stable limited disease. Vitiligo is autoimmune; peripheral leech application is unlikely to address that pathophysiology.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment
- Koebner phenomenon — new vitiligo patches at bite sites (this is the dominant risk in vitiligo)
- Bruising and tenderness for 5 to 10 days
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Post-inflammatory hyperpigmentation or hypopigmentation at bite sites
- Small bite marks that usually fade over weeks to months (rarely a pale spot stays longer)
- Delay or replacement of effective therapy with risk of disease progression
- Who should not consider this
- Patients with active progressive vitiligo (new patches in the last 6 months — needs stabilization first)
- Patients with a documented Koebnerization tendency
- Patients with segmental vitiligo (different mechanism — consider melanocyte transplant)
- Patients on topical ruxolitinib (drug interaction unknown)
- Patients with skin malignancy or atypical nevi at proposed sites
- Patients on anticoagulants, with hemophilia, or with anemia
- What to ask your clinician
- Has my vitiligo been stable for at least 6 months with no new lesions?
- Have I tried topical tacrolimus or topical ruxolitinib (Opzelura) — the only FDA-approved nonsegmental vitiligo therapy?
- Have I been offered narrow-band UVB phototherapy or excimer laser?
- Am I a candidate for surgical melanocyte transplantation for stable patches?
- What is my Koebnerization risk, and how does it impact leech therapy decisions?
- What is the realistic effect size with leech therapy versus proven options?
- What is the practitioner's experience and Aeromonas-prevention plan?
- When to seek urgent care
- Rapidly progressive new vitiligo patches (suggests active autoimmune flare)
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Bleeding from a bite site lasting more than 24 to 48 hours
- New vitiligo at the bite site itself (Koebner phenomenon)
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
What this does NOT mean
- This is not FDA-cleared for vitiligo.
- Anecdotal case reports do NOT establish efficacy versus topical ruxolitinib, NB-UVB, or melanocyte transplantation.
- Mechanism rationale does NOT address the autoimmune melanocyte destruction at the root of vitiligo.
- Leech therapy carries a real Koebner risk — new vitiligo patches at bite sites are possible.
- Leech therapy is not a substitute for topical ruxolitinib, NB-UVB phototherapy, or surgical melanocyte transplantation.
Safety cross-references
Clinical Profile
- Category
- Dermatological
- ICD-10
- L80
- Safety tier
- Medium
Evidence Summary
Vitiligo management per the AAD 2023 guideline includes topical calcineurin inhibitors (tacrolimus, pimecrolimus), topical corticosteroids, topical ruxolitinib (FDA-approved 2022 for nonsegmental vitiligo), narrow-band UVB phototherapy, and surgical melanocyte transplantation for stable limited disease. No controlled clinical study of leech therapy for vitiligo was identified in PubMed (no records), Europe PMC or ClinicalTrials.gov. Only uncontrolled reports from Ayurvedic journals were found, mostly single-patient case reports combined with other Ayurvedic treatment (for example Kulkarni 2025, periocular vitiligo; Choure 2026, a child treated with leeches plus topical and oral Ayurvedic preparations); none can establish efficacy. Its use is investigational and its rationale mechanistic only. The autoimmune pathophysiology (melanocyte destruction) is not addressed by peripheral leech application, and repigmentation is more plausibly achieved with conventional immunomodulation and phototherapy. Evidence is grade D.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)
Contraindications
- Hemophilia or another bleeding disorder
- Taking anticoagulants (blood thinners such as warfarin or heparin)
- Anemia or suppressed blood formation
- Low blood pressure, shock, collapse or fainting
- Severe wasting (cachexia)
- Intolerance of leeches or a history of severe allergic reactions
- Pregnancy
- Stomach or duodenal ulcer, erosive gastritis
- Acute infectious disease or high fever
- Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
- Drinking alcohol at the time of treatment
- No consent from the patient
- Active progressive vitiligo (consider stabilization first)
- Segmental vitiligo (different mechanism, consider melanocyte transplant)
- Koebnerization tendency (treatment trauma may extend lesions)
- Concurrent topical ruxolitinib (drug interaction unknown)
- Skin malignancy or atypical nevi at proposed site
Related Conditions
Alopecia Areata (Investigational Adjunct)
Investigational adjunct for stable patchy alopecia areata; case reports only; intralesional corticosteroids and JAK inhibitors (baricitinib, ritlecitinib) remain primary.
Plaque Psoriasis (Localized)
Investigational adjunct, not a primary treatment; a few small, mostly uncontrolled studies report lower PASI scores.
Atopic Eczema (Localized Refractory)
Investigational use for localized refractory eczema; evidence is limited to a few small studies without placebo or standard-care controls.
Livedo Reticularis
Investigational use for primary livedo reticularis; no clinical study was identified. Secondary causes (lupus, APLAS) require rheumatology referral.